Corinne Johnson
Stock Analyst at Goldman Sachs
(1.19)
# 3,596
Out of 4,905 analysts
12
Total ratings
27.27%
Success rate
-7.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Reinstates: Buy | $55 | $33.76 | +62.91% | 2 | Jul 10, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $22.07 | +49.52% | 3 | Jul 10, 2025 | |
| AMLX Amylyx Pharmaceuticals | Reinstates: Buy | $10 | $8.34 | +19.90% | 1 | Jul 10, 2025 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $18 | $9.46 | +90.27% | 1 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $132.02 | +37.86% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $26.75 | +86.92% | 3 | May 14, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $17.91 | +179.17% | 1 | Mar 13, 2024 |
Avidity Biosciences
Jul 10, 2025
Reinstates: Buy
Price Target: $55
Current: $33.76
Upside: +62.91%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $22.07
Upside: +49.52%
Amylyx Pharmaceuticals
Jul 10, 2025
Reinstates: Buy
Price Target: $10
Current: $8.34
Upside: +19.90%
Syndax Pharmaceuticals
Jul 10, 2025
Initiates: Buy
Price Target: $18
Current: $9.46
Upside: +90.27%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $132.02
Upside: +37.86%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $26.75
Upside: +86.92%
Immunovant
Mar 13, 2024
Initiates: Buy
Price Target: $50
Current: $17.91
Upside: +179.17%